Pentixapharm is a Germany-based clinical-stage biotech specializing in theranostic radiopharmaceuticals that combine diagnostic imaging and targeted therapy in a single platform. Spun out from isotope supplier Eckert & Ziegler, the company focuses on the CXCR4 receptor—implicated in blood cancers, hypertension, and other health issues—developing both the PET imaging tracer PentixaFor and the therapeutic agent PentixaTher. With phase III trials underway for marginal zone lymphoma and primary aldosteronism and early-stage therapy studies in leukemia and lymphomas, Pentixapharm is advancing a precision medicine model that “finds, fights and follows” disease progression. They've also expanded their pipeline by integrating antibody-based radionuclide conjugates through a recent acquisition of Glycotope’s discovery unit.